Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized peptide vaccine trial in pediatric and AYA patients with metastatic fusion-driven sarcomas
2024-511337-35-00Phase 2Authorised
- Sponsor
- University Hospital Tübingen
- Start
- Nov 2023
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trivalent inactivated polio vaccine in Ewing sarcoma, alveolar rhabdomyosarcoma (ARMS) and synovial sarcoma (SS), sponsored by University Hospital Tübingen. Primary endpoint: Success of treatment. Planned start Nov 2023; status: authorised.
02
Drugs
trivalent inactivated polio vaccine
03
Conditions
Ewing sarcomaalveolar rhabdomyosarcoma (ARMS)synovial sarcoma (SS)
Beyond the preview
Go deeper on 2024-511337-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511337-35-00.